OncoTargets and Therapy

Open Access Full Text Article

RETRACTION

microRNA-628 Inhibits the Proliferation of Acute Myeloid Leukemia Cells by Directly Targeting IGF-IR [Retraction]

Chen L, Jiang X, Chen H, Han Q, Liu C, Sun M. OncoTargets and Therapy. 2019;12:907–919.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised over alleged image duplication in Figures 2D, 4D and 5D with similar images from unrelated articles, specifically:

- Figure 4D, panel HL-60 NC siRNA appears to have been duplicated with a similar image in Figure 6B from Li et al, 2019 (https://doi.org/10.2147/CMAR.S210845).
- Figure 4D, panel THP-1 NC siRNA appears to have been duplicated with a similar image in Figure 5C from Wang et al, 2018 (<u>https://doi.org/10.3892/or.</u> 2018.6804).
- Figure 5D, panel HL-60 miR-NC appears to have been duplicated with a similar image in Figure 6E from Wang et al, 2019 (https://doi.org/10.3892/ijo.2019.4759).
- Figure 5D, panel HL-60 miR-628 mimics + pc-IGF -1R appears to have been duplicated with similar

images from Figure 5C from Lv et al, 2019 (<u>https://doi.org/10.2147/OTT.S208263</u>) and Figure 6D from Yun et al, 2019 (<u>https://doi.org/10.2147/CMAR.</u> <u>S198615</u>).

• Figure 5D, panel THP-1 miR-NC appears to have been duplicated with a similar image in Figure 4D from Zhao et al, 2018 (<u>https://doi.org/10.3892/ijo.</u> 2018.4615).

The authors did not respond to our queries and the Editor determined the findings of the study were no longer valid and advised for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

http://doi.org/10.2147/OTT.S339844

Received: 17 September 2021 Accepted: 17 September 2021 Published: 19 September 2021

OncoTargets and Therapy 2021:14 4847

4847

© 2021 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. The permission from Comercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/emrs.jhp).